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Runx2 is a critical transcription factor for osteoblast differen-
tiation. Regulation of Runx2 expression levels and transcrip-
tional activity is important for bone morphogenetic protein
(BMP)-induced osteoblast differentiation. Previous studies
have shown that extracellular signal-regulated kinase (Erk) acti-
vation enhances the transcriptional activity of Runx2 and that
BMP-induced Runx2 acetylation increases Runx2 stability and
transcriptional activity. Because BMP signaling induces Erk
activation in osteoblasts, we sought to investigate whether
BMP-induced Erk signaling regulates Runx2 acetylation and
stability. Erk activation by overexpression of constitutively
active MEK1 increased Runx2 transcriptional activity, whereas
U0126, an inhibitor of MEK1/2, suppressed basal Runx2 tran-
scriptional activity and BMP-induced Runx2 acetylation and
stabilization. Overexpression of constitutively activeMEK1 sta-
bilized Runx2 protein via up-regulation of acetylation and
down-regulation of ubiquitination. Erk activation increased
p300 protein levels and histone acetyltransferase activity.
Knockdown of p300 using siRNA diminished Erk-induced
Runx2 stabilization. Overexpression of Smad5 increased Runx2
acetylation and stabilization. Erk activation further increased
Smad-induced Runx2 acetylation and stabilization, whereas
U0126 suppressed these functions. On the other hand, knock-
down of Smad1 and Smad5 by siRNA suppressed both basal and
Erk-induced Runx2 protein levels. Erk activation enhanced the
association of Runx2 with p300 and Smad1. Taken together
these results indicate that Erk signaling increases Runx2 stabil-
ity and transcriptional activity, partly via increasing p300 pro-
tein levels and histone acetyltransferase activity and subse-
quently increasingRunx2 acetylation by p300. In addition to the
canonical Smad pathway, a BMP-induced non-SmadErk signal-
ing pathway cooperatively regulates osteoblast differentiation
partly via increasing the stability and transcriptional activity of
Runx2.
The bone morphogenetic proteins (BMPs)3 are members of
the transforming growth factor- superfamily and are primary
growth factors that induce formation of both cartilage and
bone. Receptors for BMP are serine/threonine kinase receptors
and consist of type I (BMPR-I) and II (BMPR-II) receptors.
After ligand binding, BMPR-I kinases are activated by BMPR-II
kinase-induced phosphorylation. R-Smad proteins are then
recruited to activated receptors and play a role in transmitting
the BMP signal from the receptor to target genes such as alka-
line phosphatase (ALP), bone sialoprotein, osteocalcin (OC),
Runx2, and Dlx5 (1, 2). In addition to the Smad pathway,
diverse intracellular signaling molecules also participate in
BMP-induced osteoblast differentiation. These are collectively
called the non-Smad pathway of BMP signaling and include
extracellular signal-regulated protein kinase (Erk), p38 mito-
gen-activated protein kinase, c-Jun N-terminal kinase, phos-
phatidylinositol 3-kinase, and protein kinases C and D (3–7).
These cooperate with and/or regulate the Smad pathway (8).
Runx2 is a transcription factor that belongs to the runt-do-
main gene family. Runx2 acts as amaster regulator for the com-
mitment of mesenchymal stem cells to the osteoblastic lineage
and regulates expression levels of osteogenic marker genes
including ALP, osteopontin, type I collagen, and OC (9–11).
Runx2-deficient mice do not form mineralized bone, whereas
mice heterozygous for Runx2 show a phenotype similar to that
in humanswith cleidocranial dysplasia (9, 11). Loss-of-function
mutations in human RUNX2 are responsible for the cleidocra-
nial dysplasia phenotype (12). These reports imply that the
appropriate gene dosage of Runx2 is crucial for bone develop-
ment. Runx2 expression is regulated by various extracellular
signals including BMP and fibroblast growth factors (FGFs)
(13–15).
In addition to transcriptional regulation, Runx2 can bemod-
ified post-translationally by phosphorylation, acetylation, and
ubiquitination, and these post-translational modifications
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seem to affect transcriptional activity and/or stability of Runx2
(16, 17). Phosphorylation of Runx2 by distinct kinases and sig-
naling pathways results in differential effects on Runx2 func-
tion and osteoblast differentiation. Runx2 transcriptional activ-
ity is decreased by phosphorylation at Ser-104 and Ser-451 (18)
or by glycogen synthase kinase 3-dependent phosphorylation
at Ser-369—Ser-373—Ser-377 (19). In contrast, Runx2 phos-
phorylation by Erk in its proline-, serine-, and threonine-rich
domain increases transcriptional activity and osteoblast differ-
entiation (20–22). Previous studies have shown that Erk is acti-
vated by various extracellular signals such as extracellular
matrix, FGF, and BMP, which all stimulate osteoblast differen-
tiation (13, 14, 23). A recent in vivo study has elucidated that
transgenic mice overexpressing a constitutively active MEK
(Mek-sp) in osteoblasts show enhanced bone formation and
that crossing Mek-sp transgenic mice to Runx2 heterozygote
mice partially rescues the phenotype of cleidocranial dysplasia
(24). These reports suggest that the MEK/Erk pathway plays a
pivotal role in osteogenesis, at least through stimulation of
Runx2 phosphorylation and transcriptional activity. However,
the molecular mechanism that links Erk activation and the
resulting Runx2 phosphorylation to enhanced Runx2 tran-
scriptional activity remains unclear.
Ubiquitination and subsequent proteasome-dependent pro-
tein degradation is an important regulatory mechanism for
control of numerous cellular processes (25). Runx2 is also selec-
tively targeted for ubiquitination of lysine residues and subse-
quent proteasomal degradation by specific ubiquitin E3 ligases
such as Smad ubiquitin regulatory factor (Smurf) (26). Cyclin
D1/CDK4-mediated phosphorylation of Runx2 at Ser-472 is
known to stimulate ubiquitination and proteasomal degra-
dation of Runx2 (27). In addition, p300 increases the Runx2
half-life as well as transcriptional activity through acetyla-
tion of specific lysine residues, precluding Smurf1-mediated
ubiquitination (28). The p300 protein is a transcriptional coac-
tivator with a histone acetyltransferase (HAT) domain (29, 30).
In contrast, histone deacetylase 4 (HDAC4) and HDAC5 have
been shown to deacetylate Runx2, allowing the protein to
undergo Smurf-mediated ubiquitination and subsequent deg-
radation (28).
Regulation of Runx2 transcriptional activity and stability is
important to BMP-induced osteoblast differentiation. BMP-2
increases p300-mediated Runx2 acetylation, enhancing the sta-
bility and transcriptional activation of Runx2 and consequently
osteoblast differentiation (28). Because Erk is also activated by
BMP-2, we aimed to investigate the role of Erk activation in
BMP-2-induced Runx2 stabilization and transcriptional activa-
tion. In this study we show that Erk activation is required for
BMP-2-induced Runx2 acetylation and stabilization, which is
at least in part achieved through increasing p300 protein levels
and HAT activity.
EXPERIMENTAL PROCEDURES
Materials—Recombinant human BMP-2 was purchased
from Cytolab (Rehovot, Israel). The easy-BLUETM, i-star
TaqTM,Maxime RT PreMix, andWEST-ZOL (plus) were pur-
chased from iNtRON Biotechnology (Sungnam, Korea). The
AccuPower RT-PreMix was purchased from Bioneer (Daejoen,
Korea) and SYBR Premix Ex TaqTM was from TaKaRa (Otsu,
Japan). The alkaline phosphatase staining kit and anti-FLAG
M2 monoclonal antibody were purchased from Sigma. Anti-
acetyl lysine, anti-phosphoserine for MAPK/CDK substrates
((PXS*P or S*PXR/K motif), anti-ubiquitin, anti-phospho-Erk,
anti-Erk antibodies, and the MEK1/2 inhibitor U0126 were
purchased from Cell Signaling Technology (Beverly, MA).
Anti-HA monoclonal antibody was purchased from Covance
(Berkley, CA), and anti-p300 antibody was from Upstate Bio-
technology (Lake Placid, NY). Anti-Myc, anti-Runx2, and anti-
actin antibodies and HRP-conjugated secondary antibodies
were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). The Lipofectamine 2000 reagent was purchased from
Invitrogen and WelFect-ExTM PLUS was from WelGENE
(Seoul, Korea). The luciferase assay systemwas purchased from
Promega (Madison, WI).
Cell Culture and ALP Staining—C2C12 and 293T cells were
maintained in DMEM supplemented with 10% fetal bovine
serum (FBS), 100 units/ml penicillin, and 100g/ml streptomy-
cin. To induce osteoblastic differentiation, C2C12 cells were
cultured in DMEM supplemented with 5% FBS and BMP-2
(200300 ng/ml). To observe the effect of Erk activation on
BMP-2-induced osteogenic differentiation, ALP activity was
examined by ALP histochemical staining. When C2C12 cells
became90% confluent, the cells were pretreated with vehicle
or 40MU0126 for 1 h and further incubated in the presence of
300 ng/ml BMP-2 for an additional 48 h. ALP staining was then
performed using the alkaline phosphatase staining kit accord-
ing to the manufacturer’s instructions.
Plasmid Constructs and Site-directed Mutagenesis—Previ-
ously reported expression plasmids and reporter vectors were
used: Myc- or FLAG-tagged Runx2 full-length type I isoform
(MRIPV N-terminal sequence) and type II isoform (MASNS
N-terminal sequence) expression vectors; pGL3–6XOSE2-luc
reporter (15, 31); constitutively active BMP receptor IB (BMPR-
IB), HA-p300, FLAG-Smad1, FLAG-Smad5,Myc-HDAC4, and
Myc-HDAC5 expression vectors (28). The constitutively active
MEK1 plasmid (pFC-MEK1) was purchased from Stratagene
(La Jolla, CA). The type II Runx2-S301A/S319A mutant was
generated by the QuikChange II site-directed mutagenesis kit
(Stratagene) according to the manufacturer’s instructions (32).
These mutants were confirmed by sequencing. The primers
used were as follows: S301A forward, 5-CCC AGGCAGGCA
CAG TCT GCC CCA CCG TGG TCC TAT GAC-3; S301A
reverse, 5-GTC ATA GGA CCA CGG TGG GGC AGA CTG
TGC CTG CCT GGG-3; S319A forward, 5-TAT CTG AGC
CAG ATG ACA GCC CCA TCC ATC CAC TCC ACC ACG-
3; S319A reverse, 5-CGT GGT GGA GTG GAT GGA TGG
GGC TGT CAT CTG GCT CAG ATA-3.
RT-PCR and Real-time PCR—Expression levels of ALP, OC
and p300 mRNA were examined by real-time PCR. Total RNA
was isolated using easy-BLUETM RNA extraction reagent.
cDNA was synthesized from 1 g of total RNA using theMax-
ime RT PreMix kit. Real-time PCR analysis was performed
using SYBR Premix Ex TaqTM and an AB 7500 Fast Real-time
PCR system (Applied Biosystems, Foster City, CA). Each sam-
ple was analyzed in quadruplicate, and target genes were nor-
malized to the reference housekeeping gene glyceraldehyde-3-
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phosphate dehydrogenase (GAPDH). Fold differences were
then calculated for each treatment group using normalized CT
values for the control. Mouse genes and their primer sequences
for real-time PCR were as follows: OC forward, 5-ATCTCA-
CCATTCGGATGAGTCT-3; OC reverse, 5-TCAGTCCAT-
AAGCCAAGCTCTCA-3; ALP forward, 5-CCAACTCTTT-
TGTGCCAGAGA-3, ALP reverse, 5-GGCTACATTGGTG-
TTGAGCTTTT-3; p300 forward, 5-GAAGAACAGCCAA-
GCACCTC-3; p300 reverse, 5-CGGTAAAGTGCCTCCAA-
TGT-3; GAPDH forward, 5-CATGTTCCAGTATGACTCC-
ACTC-3; GAPDH reverse 5-GGCCTCACCCCATTTG-
ATGT-3.
Luciferase Reporter Assay—C2C12 cells were plated in 96-
well plates, and transient transfection was performed with the
Lipofectamine Plus reagent. In each transfection, 100 ng of
expression plasmid (pcDNA3, pcDNA3-Runx2, and/or pFC-
MEK1), 100 ng of reporter plasmid (pGL3-luc or pGL3–
6XOSE2-luc), and Renilla luciferase plasmid were used as indi-
cated. After overnight recovery from transfection, the cells
were further incubated with vehicle or 40 M U0126 for 24 h.
The cells were then harvested, and luciferase activity was deter-
mined using a luciferase assay kit according to the manufactur-
er’s instructions. The data were represented as activity relative
to Renilla luciferase activity.
Immunoblot Analysis and Immunoprecipitation—After ap-
propriate treatments, the cells were washed with ice-cold PBS
twice and lysed in radioimmune precipitation assay buffer con-
sisting of 10mMTris-HCl (pH 7.5), 1 mM EDTA, 150mMNaCl,
1% Nonidet P-40, 2% SDS, 1% sodium deoxycholate, 50 mM
NaF, 0.2 mM Na3VO4, 1 mM PMSF, and a protease inhibitor
mixture. Protein concentrations were measured using BCA
reagents. Each sample containing equal amounts of proteinwas
subjected to SDS-PAGE and immunoblot analysis as described
previously (33). For immunoprecipitation, cells were washed
with ice-cold PBS twice and lysed in 1 HEPES lysis buffer
consisting of 25 mM HEPES (pH 7.5), 150 mM NaCl, 10 mM
sodium butyrate, 1% Nonidet P-40, 0.25% sodium deoxy-
cholate, 10% glycerol, protease inhibitormixture, and phospha-
tase inhibitor cocktails I and II. After measuring protein con-
centrations, 1 mg of protein from each sample was used for
immunoprecipitation with appropriate primary antibodies and
proteinG-agarose beads. Binding reactions were performed for
16 h at 4 °C with continuous rotation. The beads were collected
and washed three times with 1 HEPES lysis buffer. Bound
proteins were eluted by boiling in 1 Laemmli sample buffer
with 1 M DTT and then subjected to SDS-PAGE and immuno-
blot analysis.
Determination of Runx2 Stability—293T cells were tran-
siently transfected with Myc-Runx2, BMPR-IB, and/or MEK1
expression plasmids. Thirty hours after transfection, cyclohex-
imide (10 g/ml) was added to cells in order to inhibit new
protein synthesis. One hour after cycloheximide addition, cells
were further incubated in the presence or absence of U0126 (40
M) for the indicated times. Immunoblot analysis was then
performed.
Ubiquitination Analysis—C2C12 cells were transiently
transfected with pcDNA or MEK1 expression vectors using
WelFECT.After overnight recovery, the cells were incubated in
the presence or absence of MG132 (5 M), a proteasome inhib-
itor, for an additional 18 h. For theU0126-treated group,U0126
(40M)was added to the culture for the final 2 h. The cells were
then lysed in ice-cold lysis buffer consisting of 25 mM Tris-HCl
(pH 7.5), 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 0.2%
SDS, 5 mM N-ethylmaleimide, protease inhibitor mixture, and
phosphatase inhibitor cocktails I and II. Immunoprecipitation
with anti-Runx2 antibody and subsequent immunoblot analysis
with anti-ubiquitin antibody were performed to detect ubiq-
uitinated Runx2.
HAT Assay—The HAT assay was performed as described
previously (34). C2C12 cells were transiently transfected with
HA-p300 andMEK1 expression vectors and incubated for 48 h.
For the U0126-treated sample, U0126 (40M) was added to the
culture for the final 2 h. Cell lysates were prepared using 1
HEPES lysis buffer described above, and immunoprecipitation
was performed with anti-p300 antibody or with control IgG
overnight at 4 °C. The beads were then washed three times and
incubatedwith 1g (50 pmol) histones and [14C]acetyl CoA (50
Ci/l, 1000 pmol/l, Amersham Biosciences) for 30 min at
37 °C. SDS-PAGE was then performed using 5 l of each reac-
tion mixture. The 14C-labeled acetylated histone level was
detected using phosphorimaging, and Coomassie staining of
gels was performed to check equal loading of histone.
Gene Knockdown by Small Interfering RNA (siRNA)—ON-
TARGETplus SMARTpool siRNAs for human p300, SMAD1,
and SMAD5 genes and a non-targeting siRNA (control siRNA)
were purchased from Dharmacon (Chicago, IL). ON-TAR-
GETplus SMARTpool siRNAswere amixture of 4 siRNAs, pro-
viding advantages in both potency and specificity. Transfection
of siRNA into 293T cells was performed according to the man-
ufacturer’s instructions. The second transfection with Myc-
Runx2 and MEK1 expression vectors was performed 6 h later,
and cells were incubated for an additional 32 h. Whole cell
lysates were then prepared, and immunoprecipitation and/or
immunoblot analysis was performed.
Statistical Analysis—All results were expressed as mean 
S.E. The statistical significance was analyzed by Student’s t test.
A p value 0.01 was considered to be statistically significant.
RESULTS
Erk Activation Is Involved in BMP-2-induced Osteoblast
Differentiation—To investigate the role of activated Erk in
BMP-2-induced osteoblast differentiation, we used pluripotent
mesenchymal C2C12 cells that can be differentiated into osteo-
blasts by BMP-2 treatment (35). We first examined whether
BMP-2 induces Erk activation in C2C12 cells (Fig. 1A). BMP-
2-induced Erk phosphorylation was observed within 5 min and
persisted for at least 24 h, although there was a fluctuation in
Erk phosphorylation level. This result is similar to a previous
report (36). We then investigated the role of Erk activation in
BMP-2-induced osteoblast marker gene expression using
U0126, a specific inhibitor of Erk upstream kinases MEK1/2.
ALP andOCwere used as phenotypicmarkers for early and late
differentiation, respectively (37). ALP staining showed that
blocking Erk activation by U0126 clearly suppressed ALP activ-
ity (Fig. 1B). Semiquantitative RT-PCR and real-time PCR
results showed that the ALP mRNA level was greatly increased
Erk Increases p300-mediated Runx2 Stabilization
36412 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285•NUMBER 47•NOVEMBER 19, 2010
 at Y
O
N
SEI U
N
IV
ERSITY
 on D
ecem
ber 10, 2013
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
by BMP-2, whereas the OC mRNA level was weakly induced
(Fig. 1, C and D). U0126 significantly suppressed BMP-2-in-
duced expression of both ALP and OC. These results confirm
previous reports that Erk activation is necessary for BMP-2-
induced osteoblast marker gene expression (21, 36). We next
examined whether the transcriptional activity of Runx2 is reg-
ulated by Erk activation. We performed reporter assays using
the pGL3–6XOSE2-luc vector that contains six tandem repeats
of a Runx2 binding element in the promoter of the mouse OC
gene (15). MEK1 overexpression alone enhanced luciferase
activity similar to Runx2 overexpression and synergistically
increased Runx2-induced luciferase activity (Fig. 1E). On the
other hand, U0126 significantly suppressed Runx2 transcrip-
tional activity (Fig. 1F). MEK1-stimulated luciferase activity
seems to be due to endogenous Runx2 in C2C12 cells, and this
result is similar to the previous report showing thatMEK1 stim-
ulated OSE2-driven reporter activity only in Runx2-positive
cells (38). These results confirm previous reports that Erk acti-
vation stimulates Runx2 transcriptional activity (38) and indi-
cate that Erk activation is necessary for Runx2 transcriptional
activation.
Erk Activation Increases Runx2 Protein Stability and
Acetylation—Because it has been reported that BMP-2 in-
creases Runx2 protein stability aswell as transcriptional activity
(28), we next examined whether Erk activation is involved in
BMP-2-induced Runx2 protein stabilization. C2C12 cells were
incubated with BMP-2 and/or U0126 for 48 h (Fig. 2A). At this
time point, Erk activation was still observed in the BMP-2-
treated group. BMP-2 clearly increased endogenous Runx2
protein levels, and U0126 treatment completely abolished the
effect of BMP-2 on Runx2 protein expression. To rule out a
regulatory effect of Erk activation on Runx2 transcription, we
observed the effect of Erk activation on exogenously expressed
FLAG-Runx2 (Fig. 2B). Overexpression of constitutively active
BMPR-IB increased the level of phosphorylated Erk, andU0126
suppressed both basal and BMPR-induced Erk activation.
BMPR-IB increased FLAG-Runx2 protein levels, whereas
U0126 decreased both basal and BMPR-IB-induced FLAG-
Runx2 levels. Because a previous report had shown that BMP-2
increases Runx2 protein stability via Runx2 acetylation (28), we
also looked for an effect of Erk activation on acetylated FLAG-
Runx2 levels (Fig. 2B). Similar to FLAG-Runx2 protein levels,
BMPR-IB significantly increased acetylated FLAG-Runx2,
whereas U0126 decreased this effect. We also observed that
BMP-2 treatment increased exogenously expressed Myc-
Runx2protein levels and that this increase could be detected 8h
after exposure to BMP-2 (Fig. 2C). We next examined whether
the Erk-induced increase in Runx2 protein levels is due to
increased protein stability (Fig. 2D). A previous report showed
that the exogenously expressed Runx2 protein half-life was5
h in 293T cells but that BMP signaling extended it to 50 h (28).
Similar to that report, BMPR-IB overexpression significantly
delayed Runx2 protein degradation. U0126, however, blocked
BMPR-IB-induced stabilization and enhanced Runx2 degrada-
tion further than the control. In contrast, MEK1 overexpres-
sion dramatically increased Runx2 protein stability. These
results suggest that Erk signaling is critical for themaintenance
of Runx2 protein stability. Because the above data showed that
Erk activation increased Runx2 acetylation and protein stabil-
ity, we next analyzedwhether Erk activation affects endogenous
Runx2 ubiquitination (Fig. 2, E and F). In the presence of
MG132, a proteasomal inhibitor, the polyubiquitinated Runx2
ladder increased, suggesting that proteasomal degradation of
ubiquitinated Runx2 is continuously in progress inC2C12 cells.
U0126 increased Runx2 ubiquitination, whereasMEK1 overex-
pression suppressed it (Fig. 2,E and F, upper panel). Both nonu-
biquitinated Runx2 and acetylated Runx2 protein levels were
increased by MEK1 but decreased by U0126 (Fig. 2, E and F,
middle and lower panels). These results indicate that Erk
enhances Runx2 stability via stimulation of Runx2 acetylation
and concomitant diminution of Runx2 ubiquitination.
p300-mediated Runx2 Acetylation Is Essential for Erk-in-
duced Runx2 Stabilization—Previously it had been reported
that overexpression of HDAC4 or HDAC5 results in deacetyla-
tion and destabilization of Runx2, whereas their knockdown by
FIGURE 1. Erk activation is involved in BMP-2-stimulated osteoblast dif-
ferentiation. A, BMP-2 induced Erk activation. C2C12 cells were serum-
starved for 16 h and treated with BMP-2 for the indicated times. Whole cell
lysates were prepared and subjected to immunoblot analyses. B–D, Erk inhi-
bition by U0126 suppressed BMP-2-induced ALP and OC expression. C2C12
cells were treated with BMP-2 and/or U0126 (40 M) for 2 days and then ALP
histochemical staining (B) and semiquantitative RT-PCR (C and D, upper pan-
els) or real-time PCR (C and D, lower panel) were performed. Data represent
the mean  S.E. (n  4). *, p  0.01. E and F, Erk signaling increased Runx2
transcriptional activity. C2C12 cells were transfectedwith pGL3–6XOSE2-Luc
andFLAG-Runx2or a constitutively activeMEK1expressionvector. After over-
night recovery from transfection, cells were incubated in the presence or
absence of U0126 for an additional 24 h. Data are shown as activity relative to
Renilla luciferase activity and represent the mean  S.E. (n  6). * p  0.01,
compared with control; #, p  0.01, compared with FLAG-Runx2 overex-
pressed group.
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siRNA enhances Runx2 acetylation and stabilization (28).
Therefore, to further verify that Runx2 acetylation is indispen-
sible for Erk-mediated Runx2 stabilization, we induced
deacetylation of Runx2 by overexpression of Myc-HDAC4 or
Myc-HDAC5 in 293T cells (Fig. 3A). As expected, Runx2 acety-
lation was decreased in the presence of HDAC4 and HDAC5.
Moreover, overexpression of HDAC4 or HDAC5 blocked
MEK1-induced Runx2 acetylation and stabilization. These
results indicate that Erk-induced Runx2 stabilization requires
Runx2 acetylation. To further confirm the necessity for p300-
mediated acetylation in Erk-induced Runx2 stabilization, we
knocked down the endogenous p300 by siRNA (Fig. 3B). The
efficiency of p300 siRNA was confirmed by immunoblot anal-
ysis. MEK1 overexpression also significantly increased endog-
enous p300 protein levels. siRNA for p300 decreased basal as
well as Erk-induced p300 protein expression. Furthermore,
knockdown of p300 suppressed Erk-induced Runx2 acetylation
and stabilization. These results indicate that p300 is involved in
Erk-induced Runx2 acetylation.
Erk Activation Increases p300 Protein Levels and HAT Activ-
ity—Because the above data showed that Erk activation
increases p300 protein levels, we examined whether p300
mRNA levels are also changed by Erk activation. For this,
C2C12 cells were transiently transfectedwith pcDNAorMEK1
expression plasmids and incubated for 13 h. The mRNA levels
for p300 were then examined using real-time PCR (Fig. 4A).
Dissimilar to the effect on p300 protein levels, Erk activation
did not exert a significant effect on p300mRNA levels. Because
Erk activation increased exogenously expressed p300 protein as
well as the endogenous form, it is likely that Erk regulates p300
at the post-transcriptional level. A previous study had demon-
strated that Erk2 increases p300 HAT activity directly by phos-
phorylation (39). Therefore, we assayed whether overexpres-
sion ofMEK1 increases p300 phosphorylation in 293T cells. Erk
activation increased p300 phosphorylation as well as its total
protein level (Fig. 4B). Because p300 has auto-acetylating activ-
ity (29), we also checked the acetylation level of p300 (Fig. 4B).
Similar to phosphorylation, p300 acetylation is also increased
by Erk activation. In accordance with the p300 acetylation data,
MEK1 increased p300 HAT activity, whereas U0126 slightly
decreased the activity (Fig. 4C). These results indicate that Erk
activation increases p300 protein levels as well as HAT activity.
FIGURE 2. Erk activation increases Runx2 acetylation and stability,
whereas it decreases Runx2 ubiquitination. A, U0126 decreased BMP-2-
induced Runx2 protein expression. C2C12 cells were pretreated with vehicle
or U0126 for 1 h and further incubated in the presence or absence of BMP-2
(200 ng/ml) for an additional 48 h. Endogenous Runx2 protein levels were
determinedby immunoprecipitationand immunoblot analysis.B, U0126 sup-
pressed constitutively active BMP type IB (BMPR-IB)-induced increase in
Runx2protein levels andacetylation. C2C12 cellswere transiently transfected
with FLAG-Runx2 and BMPR-IB expression plasmids and incubated for 24 h.
When indicated, the cells were incubated with U0126 for the last 3 h. Immu-
noprecipitation (IP) and immunoblot (IB) analysis were then performed. AcK,
anti-acetylated lysine antibody. C, BMP-2 increased exogenously expressed
Myc-Runx2 protein levels. C2C12 cells were transfected with Myc-Runx2,
incubated for 8 or 24 h in the presence of BMP-2, and subjected to IB analysis.
D, Erk activation by BMPR-IB or MEK1 expression stabilized Runx2 protein,
whereas U0126 enhanced degradation of Runx2. 293T cells were transiently
transfectedwithMyc-Runx2 and concomitantly with either BMPR-IB or MEK1
as indicated. Thirty hours after transfection the cells were treated with cyclo-
heximide (CHX, 10 g/ml) in the presence or absence of U0126 for the indi-
cated times. The levels of Myc-Runx2 and actin were determined by IB analy-
sis. E and F, U0126 increased, whereas Erk activation decreased Runx2
ubiquitination (upper panel). C2C12 cells were treated with vehicle or 5 M
MG132 for 18 h. When indicated, U0126 was added for the last 3 h (E). C2C12
cells were transfectedwith aMEK1 expression vector, incubated for 24 h, and
treatedwith vehicle orMG132 for anadditional 18h (F). Ubiquitinatedendog-
enous Runx2 was detected by IP with an anti-Runx2 antibody and subse-
quent IB with an anti-ubiquitin (Ub) antibody. Nonubiquitinated Runx2 and
acetylated Runx2were also examined using the same cell lysates (middle and
lower panels).
FIGURE 3. Runx2 acetylation and p300 are required for Erk-induced
Runx2 stabilization. A, overexpression of HDAC4 or HDAC5 blocked an Erk-
mediated increase in Runx2 protein and acetylation. 293T cells were tran-
siently transfected with FLAG-Runx2, MEK1, Myc-HDAC4, and Myc-HDAC5
expression vectors as indicated. Twenty-four hours after transfection, IP and
IB analysis was performed. B, knockdown of p300 using siRNA suppressed
Erk-mediatedRunx2acetylation and stabilization. 293T cellswere transfected
with siRNAs forp300 (sip300) andanon-targeting control siRNA (siControl). Six
hours after transfection, a second transfection with Myc-Runx2 and MEK1
expression vector was performed, and the cells were incubated for an addi-
tional 32 h, then IP and IB analysis was performed. AcK, anti-acetylated lysine
antibody.
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We next asked whether increasing p300 expression can over-
come the need for further Erk activation to increase Runx2
stability. Transient transfection of 293T cells with increasing
amounts (39 g) of HA-p300 expression vector induced
expression of HA-p300 in a dose-dependent manner (Fig. 4D).
Concomitant transfection of 3 g of HA-p300 with MEK1
induced total and acetylated HA-p300 more than with 6 g of
HA-p300. In addition, the Myc-Runx2 stabilization effect was
stronger for 3 g of HA-p300/MEK1-transfected cells than for
6 g of HA-p300-transfected cells. However, transfection of 9
g of HA-p300 induced higher levels of total and acetylated
p300 protein expression and consequent stabilization of Runx2
than transfection of 3g ofHA-p300/MEK1, suggesting that an
increase in p300 protein levels is sufficient to increase Runx2
protein stability in the presence of basal Erk activation (Fig. 4D).
We next examined whether BMPR signaling increases p300
protein levels and the association of p300 and Runx2 in C2C12
cells. Because it is difficult to detect endogenous p300 protein in
C2C12 cells using immunoblot analysis, we examined the effect
of BMPR activation using exogenously expressed HA-p300.
Interactions between p300 and endogenous Runx2 were ob-
served by co-immunoprecipitation with anti-HA antibody and
immunoblot analysis with anti-Runx2 antibody (Fig. 4E). The
results showed that BMPR-IB overexpression increased HA-
p300 protein levels, whereas U0126 treatment decreased both
basal and BMPR-IB-induced HA-p300 protein levels. In addi-
tion, the association of endogenous Runx2 and HA-p300 was
increased by BMPR-IB, whereas it was suppressed by U0126.
These results suggest that BMPR-IB-induced Erk activation
increases Runx2 acetylation via increasing p300 protein and
HAT activity and consequently increasing the association of
p300 and Runx2.
Runx2 Stabilization Requires Both Smad1/5 and Erk Activa-
tion—A previous report demonstrated that overexpression of
Smad1 and Smad5 induces Runx2 acetylation, whereas knock-
down of these by siRNA interferes with p300-mediated Runx2
acetylation, suggesting that Smad1/5 are necessary for BMP-
mediated Runx2 acetylation (28). Because the above data
showed that Erk activation is also essential for BMPR signal-
induced Runx2 acetylation and stabilization, we next analyzed
the effect of Erk activation on Smad1/5-induced Runx2 acety-
lation and stabilization. FLAG-tagged Smad1 and Smad5 were
overexpressed in 293T cells, and the effect of Erk activation or
inhibition was observed (Fig. 5, A and B). Smad1 overexpres-
sion alone did not show a significant effect on Runx2 acetyla-
tion and stability, whereas Smad5 noticeably increased Runx2
acetylation and stability. In the presence of Smad1/5 overex-
pression,MEK1 greatly enhanced Runx2 acetylation and stabil-
ity, whereas U0126 decreased Runx2 acetylation and stability
below basal levels. Because overexpressed Smad1 or 5 alone did
not show a strong effect on Runx2 acetylation and stability, we
overexpressed HA-p300 concomitantly with FLAG-Smad1/5.
Overexpression of HA-p300 synergistically enhanced Smad1-
and Smad5-induced Runx2 acetylation and stabilization (Fig.
5C). MEK1 activation further enhanced the effect of HA-p300,
whereas U0126 suppressed the effect of HA-p300 and Smad1/5
(U0126 data not shown). These results strongly indicate that
Erk signaling is necessary for BMP/Smad-induced Runx2
acetylation. To further define the requirement for Smad1/5 in
Erk-induced Runx2 stabilization, we knocked down the endog-
enous SMAD1 and SMAD5 by siRNA. The efficiency of siRNA
was confirmed by immunoblot analysis (Fig. 5D). Knockdown
of SMAD1/5 decreased both the basal and Erk-induced Runx2
protein levels, but the Erk-induced increase in Runx2 stability
was still observable. These results suggest that both Smad1/5
and Erk activation are required for full stabilization of Runx2 by
BMP signaling.
FIGURE 4.Erk activation increasesprotein levels andHATactivity of p300
and the association of Runx2 and p300. A, Erk activation did not signifi-
cantly increase p300 mRNA levels. C2C12 cells were transiently transfected
with a MEK1 expression vector and incubated for 13 h. Total RNA was then
prepared, and real-time PCRwas performed. B and C, Erk activation increases
p300 protein levels and HAT activity. 293T cells were transiently transfected
with HA-p300 and MEK1. Forty-eight hours after transfection, whole cell
lysates were prepared for IP and/or IB analysis. When indicated, U0126 was
used for the last 2 h (C). AcK, anti-acetylated lysine antibody. A HAT assay was
performed using immunoprecipitates with anti-p300 antibody or with con-
trol IgG, and 14C-labeled acetylated histone levels were detected by phos-
phor-imaging (C, upper panel). Coomassie staining shows equal loading of
histonemixture used for HAT assay (C,middle panel), and IB results represent
HA-p300 expression levels of cell lysates (C, lower panel). D, Erk activation
increased p300 acetylation, phosphorylation, and protein levels. The Runx2
protein level was related to the acetylated p300 protein level. 293T cells were
transiently transfected with Myc-Runx2 and increasing amounts of HA-p300
expression vector. When indicated, MEK1 was also overexpressed. Forty-
eight hours after transfection, whole cell lysates were prepared for IP and/or
IB analysis. Densitometry analysis results were provided under the respective
bands. P-S, anti-phosphoserine antibody. E, U0126 suppressed the physical
association between Runx2 and p300. C2C12 cells were transiently trans-
fected with HA-p300 and BMPR-IB expression vectors and incubated in the
presenceor absenceofU0126 for 48h.Whole cell lysateswere thenprepared,
and IP and/or IB analysis was performed.
Erk Increases p300-mediated Runx2 Stabilization
NOVEMBER 19, 2010•VOLUME 285•NUMBER 47 JOURNAL OF BIOLOGICAL CHEMISTRY 36415
 at Y
O
N
SEI U
N
IV
ERSITY
 on D
ecem
ber 10, 2013
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
ErkActivation Increases theAssociation of Runx2with Smad1
and p300—A previous study had demonstrated that the asso-
ciation of Runx2 and Smad1/5 is essential for BMP2-induced
osteogenic induction of C2C12 cells and that the physical inter-
action between Runx2 and Smads is dependent on Erk-medi-
ated phosphorylation of Runx2 (40). In addition, it had been
demonstrated that Smad1/5 stimulates p300-mediated Runx2
acetylation by facilitating their physical interaction (28). There-
fore, we examined whether BMP-2-induced Erk activation
enhances the interaction between Runx2, Smad1, and p300 by
co-immunoprecipitation. C2C12 cells were transfected with
Myc-Runx2, FLAG-Smad1, and HA-p300 expression plasmids
and treated with BMP-2 in the presence or absence of U0126
(Fig. 6A). BMP-2 increased protein levels of Runx2 and p300 as
well as the association between them, whereas U0126 treat-
ment diminished the BMP-2-induced effect.We also examined
whether MEK1 overexpression enhances the interaction be-
tween Runx2, Smad1, and p300 in 293T cells (Fig. 6B). Overex-
pression of MEK1 increased the interaction between p300 and
Smad1 as well as the interaction between p300 and Runx2. Fur-
thermore, MEK1 enhanced interaction between Runx2 and
Smad1, suggesting that Erk activation increases complex for-
mation between Runx2, Smad1 and p300. Recently it has been
reported that Ser-301 and Ser-319 of type II Runx2 are directly
phosphorylated by Erk and that they are responsible for Erk-
induced transcriptional activation of Runx2 (32). Therefore, we
further looked for whether S301A/S319A mutation exerts any
effect on Erk-induced Runx2 stabilization. To address this
issue, 293T cells were transiently transfected with HA-p300,
FLAG-Smad1, and MEK1 together with wild type Myc-Runx2
FIGURE 5. Both Smad1/5 and Erk activation are required for Runx2 stabi-
lization. A–C, Erk activation further enhanced Smad1/5-induced Runx2 sta-
bilization, whereas U0126 blocked it. 293T cells were transiently transfected
withMyc-Runx2, FLAG-Smad1, FLAG-Smad5, HA-p300, andMEK1 expression
vectors as indicated and incubated for 24 h. When indicated, cells were
treated with U0126 for the last 2 h. IP and/or IB analysis was then performed.
AcK, anti-acetylated lysine antibody. D, knockdown of Smad1/5 decreased
both the basal and Erk-induced Runx2 protein levels. 293T cells were trans-
fectedwith siRNAs for Smad1 and -5 (siSmad1/5) and a non-targeting control
siRNA (siControl), and a second transfection with Myc-Runx2 and MEK1
expression vectorswas performed 6h later. After an additional incubation for
32 h, IP and IB analysis was performed.
FIGURE 6. Erk activation increases the association between Runx2,
Smad1 and p300. A, C2C12 cells were transiently transfected with Myc-
Runx2, FLAG-Smad1, andHA-p300 expression vectors and incubated for 24 h
in the presence or absence of BMP-2 (200 ng/ml) and/or U0126 (40 M). IP
and/or IB analysis was then performed. Densitometry analysis results were
providedunder the respectiveband.B, 293T cellswere transiently transfected
with Myc-Runx2, FLAG-Smad1, HA-p300, and MEK1 expression vectors as
indicated and incubated for 24 h. IP and/or IB analysis was then performed.
C andD, S310A/S319Amutation reduces Erk activation-induced Runx2 acety-
lation and stabilization. C, 293T cells were transiently transfected with wild
type Myc-Runx2 (WT) or Myc-Runx2-S301A/S319A (SA-301/319) concomi-
tantlywith FLAG-Smad1, HA-p300, andMEK1 expression vectors as indicated
and incubated for 24 h. IP and/or IB analysis was then performed. AcK, anti-
acetylated lysine antibody, P-S, anti-phosphoserine antibody. D, C2C12 cells
were transiently transfected with WT or SA mutant Myc-Runx2 expression
plasmids and were treated with BMP-2 (80 ng/ml) for 18 h as indicated. IP
and/or IB analysis was then performed.
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or Myc-Runx2-S301A/S319A expression vectors (Fig. 6C). As
expected, MEK1-induced phosphorylation was decreased in
Myc-Runx2-S301A/S319A mutant. Furthermore, S301A/
S319A mutation diminished MEK1-induced association of
p300, Runx2, and Smad1, resulting in reduced levels of Runx2
acetylation and protein stabilization. In addition, we examined
the effect of Runx2 SA mutation on BMP-2-induced Runx2
acetylation and stabilization (Fig. 6D). Runx2 SA mutation
reduced the basal Myc-Runx2 protein expression and acetyla-
tion levels as well as BMP-2-induced acetylation. Our data indi-
cate that Erk-induced phosphorylation of Runx2 is necessary
for complex formation between Runx2, Smad1, and p300 and
consequent Runx2 acetylation and stabilization.
DISCUSSION
Runx2 is a master transcription factor for osteoblast differ-
entiation and bone formation (11, 41). BMP signaling has been
shown to be required for Runx2-dependent osteoblast differen-
tiation (42). In addition to stimulation of Runx2 transcription,
BMP-2-activated R-Smads enhance the expression of osteo-
blast differentiation marker genes partly via synergistic actions
with Runx2 (14). Furthermore, BMP-2-activated Smad1/5
increases p300-mediated acetylation and stabilization of Runx2
as well as transcriptional activity of Runx2 (28). In this study we
provide another clue for the role of BMP signaling in Runx2
regulation by showing that BMP-2-induced Erk increases
acetylation and stability of Runx2 via increasing p300 protein
levels and HAT activity. In this study we demonstrate that (i)
BMP-2 induced Erk activation, (ii) BMP-2-induced expression
of ALP and OC was suppressed by U0126 treatment, (iii) tran-
scriptional activity of Runx2was increased byErk activation but
suppressed by U0126 treatment, (iv) Erk activation increased
acetylation and stability of Runx2, while decreasing ubiquitina-
tion of Runx2, (v) induction of Runx2 deacetylation by overex-
pression of HDAC4 or -5 or knockdown of p300 expression
abolished Erk-mediated Runx2 stabilization, (vi) Erk activation
increased p300 protein levels, HAT activity, and the association
of Runx2 with p300, (vii) both Erk and Smad1/5 signaling are
involved in Runx2 acetylation and stabilization, and (viii) Erk
activation increases formation of a complex composed of
Runx2, Smads, and p300.
The Erk signaling pathway is one of the major links between
the cell surface and nucleus to control diverse functions includ-
ing cell proliferation, differentiation, migration, and survival
(43). Although many studies have reported that the Erk path-
way is activated by various extracellular signals including
growth factors (22, 44, 45), extracellular matrix (21), and
mechanical force (46), it has been controversial whether Erk
signaling plays an important role in the modulation of osteo-
blast differentiation in vivo. However, a recent study conclu-
sively established a pivotal function for Erk signaling in osteo-
blast differentiation and skeletal development using transgenic
mice expressing dominant negative or constitutively active
MEK1 protein (24). Furthermore, the authors demonstrated
that the effects of transgenes were maximized in the back-
ground of a Runx2 heterozygote, suggesting that activation of
Erk signaling somehow helps overcome haploinsufficiency of
Runx2 in Runx2/mice. Although Erk activation is known to
increase transcriptional activity of Runx2 (38, 47), the molecu-
lar mechanism by which Erk signaling helps to overcome hap-
loinsufficiency for Runx2 remains unclear.
Phosphorylation, acetylation, and ubiquitination are im-
portant post-translational modifications of Runx2 that reg-
ulate Runx2 stability and/or transcriptional activity (16, 17).
Althoughprevious reports showed that Runx2phosphorylation
and transcriptional activity were stimulated by the Erk signal-
ing pathway (38, 48) and BMP-2-activated Smads increased
Runx2 acetylation, stability, and transcriptional activity (28),
there had been no study linking BMP-induced Erk signaling to
the regulation of Runx2 acetylation and stability. In this study
we provide evidence that Erk activation increases Runx2 acety-
lation and stability via increasing p300 protein levels and HAT
activity as well as its association with p300. Because a previous
report has clearly demonstrated that p300-mediated acetyla-
tion of Runx2 is essential not only for Runx2 stabilization but
also for its transcriptional activity (28), our results imply that
Erk activation increases the transcriptional activity of Runx2 by
enhancing its associationwith p300 and subsequent acetylation
and stabilization of Runx2.
Regulation of protein stability and/or transcriptional activity
by cooperative post-translational modifications is also well
known for transcription factors other thanRunx2. For instance,
stability of the tumor suppressor p53 is increased by p300/CBP-
mediated acetylation, whereas it is negatively regulated by
MDM2-HDAC1 complex-mediated deacetylation (49). The
p300-dependent increase in Runx3 acetylation increased its
stability and transcriptional activity (50). The ER81 protein, a
transcription factor of the ETS family, is a downstream effector
of the proto-oncoproteins HER2/Neu and Ras, which stimulate
not only ER81 phosphorylation but also the HAT activity of
p300 and P/CAF and thereby jointly regulate ER81 stability,
DNA binding, and transactivation (51). Furthermore, Ras/
Erk2-mediated phosphorylation of Ets-1 and Ets-2 activates
them by increasing p300/CBP recruitment and binding (52).
In addition to Erk, several kinases are known to regulate
Runx2 transcriptional activity and/or stability by phosphory-
lating Runx2. FGF2 stimulates Runx2 transcriptional activity
via protein kinase C-dependent phosphorylation of Ser-247
(53), and parathyroid hormone increases Runx2 transcriptional
activity via protein kinase A-dependent phosphorylation of
Ser-347 (54). In contrast, glycogen synthase kinase 3 inhibits
Runx2 transcriptional activity via phosphorylation of Ser-
369—Ser-373—Ser-377 (19), and the cyclinD1-CDK4 complex
induces Runx2 degradation via phosphorylation of Ser-472
(27). Despite these reports, little information has been available
concerning howRunx2 phosphorylation regulates its transcrip-
tional activity and/or stability.
Regarding the regulation of Runx2 protein stability, it has
been reported that ubiquitination of Runx2byE3 ligases such as
Smurf1 and WWP1 promotes its degradation, whereas acety-
lation by p300 stabilizes it via prevention of ubiquitination (28,
55, 56). In this study an Erk-induced increase in Runx2 acetyla-
tion was accompanied by enhanced binding of p300 to Runx2.
Because total protein levels for both p300 and Runx2 were
increased by Erk activation, it is not clear whether the increased
association between Runx2 and p300 is simply a consequence
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of protein increase or of Erk-induced phosphorylation of Runx2
and p300 that affects their affinity for each other. Based on a
recent report showing that Ser-301 and Ser-319 are the major
phosphorylation target sites of Erk and are necessary for Erk-
induced transcriptional activation of Runx2 (32), we examined
the effect of S301A/S319A mutation on Erk-induced Runx2
acetylation and stabilization. Our data showed that S301A/
S319A mutation diminishes Erk-induced association of p300
and Runx2 as well as Runx2 acetylation and stabilization. These
results suggest that Erk-mediated phosphorylation of Runx2
enhances the association of Runx2 and p300 and consequent
Runx2 acetylation and stabilization.
Although it is not clear whether p300 is the only HAT that
regulates Runx2 acetylation, p300 knockdown data indicate
that p300 plays an important role in Erk-induced Runx2 acety-
lation and stabilization. Recently, it was demonstrated that
Erk2 directly phosphorylates p300 and increases its HAT activ-
ity (39). In addition, the study showed that phosphorylation of
p300 confers a higher affinity for the Sp1 transcription factor.
We also observed that MEK1 overexpression increased p300
protein levels as well as its phosphorylation and HAT activity.
In addition, when we compared the effects on Runx2 protein
levels, it appears that acetylated p300 protein levels influence
Runx2 stabilization. Because p300 has auto-acetylating activity
(29, 30), it is assumed that acetylated p300 levels reflect its HAT
activity. Furthermore, knockdown of p300 using siRNA sup-
pressed Erk-induced Runx2 acetylation and stabilization.
Therefore, our results imply that an Erk-induced increase in
p300 protein levels and HAT activity is involved in the Erk-
mediated increase in Runx2 acetylation and stabilization.
Because Erk activation increased both endogenous and exog-
enously expressed p300 protein but did not significantly affect
p300 mRNA levels, it is likely that Erk increases p300 protein
levels via post-transcriptional regulation, necessitating further
studies.
Jeon et al. (28) have also demonstrated that Smad5 and
BMPR-IB synergistically increase Runx2 acetylation. Similar to
that report, our results show that Smad5-induced Runx2 acety-
lation was robustly stimulated by Erk activation, whereas
knockdown of Smad1/5 suppressed Runx2 acetylation and sta-
bilization. Because U0126 treatment almost completely abol-
ished Smad5-induced Runx2 acetylation, basal Erk activation
seems to be required for Smad5-induced Runx2 acetylation.
Although overexpression of Smad1 or Smad5 led to self-activa-
tion by inducing C-terminal phosphorylation, significant acti-
vation of Erk was not observed by Smad1/5 overexpression,
suggesting that basal Erk activation signals may come from the
culture environment but not from Smad1/5 overexpression
(data not shown). These results indicate that BMP-2-induced
Runx2 acetylation requires both Smad activation and non-
Smad Erk activation. The relative roles for Smad1/5 and Erk in
Runx2 acetylation are not clear. Previous studies have demon-
strated that the association of Runx2 and Smad1/5 is essential
for BMP2-induced osteogenic induction of C2C12 cells and
that the physical interaction betweenRunx2 and Smad depends
on Erk-mediated phosphorylation of Runx2 (40). In addition,
Jeon et al. (28) demonstrated that Smad1/5 stimulates p300-
mediated Runx2 acetylation by facilitating their physical inter-
action.Our results also show that Erk activation byMEK1 over-
expression greatly enhanced the association of Runx2, Smad1,
and p300. Furthermore, S310A/S319A mutation reduced Erk-
induced formation of a complex composed of p300, Smad1, and
Runx2. Taking these reports and our results together, we can pro-
pose a model for the relative roles of BMP-activated Smads and
Erk activation onRunx2 acetylation. Activated Erk increases p300
levels and its HAT activity as well as phosphorylation of Runx2.
Smad1/5 then recruits p300 and binds to phosphorylated Runx2,
thereby increasing the physical interaction between Runx2 and
p300 and subsequent Runx2 acetylation.
In summary, we show here that BMP-activated Erk increases
Runx2 acetylation and stability at least in part via up-regulating
p300 protein levels andHAT activity and that both R-Smad and
non-Smad Erk signaling is required for BMP-induced Runx2
acetylation and stabilization. Further study is necessary to ver-
ify whether Erk-mediated phosphorylation of Runx2 and/or
p300 is necessary for direct binding between the two proteins
and/or increases their binding affinity.
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